

15w/1648

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

09/910,483

Filing Date

July 19, 2001

First Named Inventor

Fang Fang et al

Art Unit

1648

Examiner Name

Le Emily M.

Attorney Docket Number

E3799-00010

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Duane Morris LLP		
Signature			
Printed name	James W. Collett		
Date	October 12, 2005	Reg. No.	46,636

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Roxanne Ippolito	Date	October 12, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)	Group Art Unit: 1648
)	
Fang Fang et al.)	Examiner: Le, Emily M.
)	
Serial No.: 09/910,483)	Confirmation No.: 3201
)	
Filed: July 19, 2001)	Customer No.: 53897
)	
For: HUMANIZED ANTIBODIES.)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97-1.98

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed after receipt of an Office Action on the merits of the above captioned application. Thus, it is believed that a fee of \$180.00 is due in connection with this submission. The Commissioner is hereby authorized to charge the requisite fee, or any fees that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 04-1679.

In accordance with 37 C.F.R. §1.56 and 37 C.F.R. §§1.97-1.98, this Information Disclosure Statement, including Forms PTO/SB/08 (3 pages) and cited documents, is provided herewith.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

October 12, 2005
Date of Deposit

Roxanne Ippolito

Substitute Form PTO-1449 (Mandatory) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3799-00010	Application No. 09/910,483
	Applicant Fang Fang et al.		
	Filing Date July 19, 2001	Group Art Unit 1648	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,698,420	10/1987	Urnovitz			
	AB	4,946,778	08/1990	Ladner			
	AC	5,077,195	12/1991	Blalock			
	AD	5,081,584	01/14/1992	Omichinski			
	AE	5,223,409	06/29/1993	Ladner			
	AF	5,260,203	11/1993	Ladner			
	AG	5,455,030	10/1995	Ladner			
	AH	5,491,074	02/1996	Aldwin			
	AI	5,565,332	10/1996	Hoogenboom			
	AJ	5,573,925	11/1996	Halazonetics			
	AK	5,582,996	12/1996	Curtis			
	AL	5,716,805	02/1998	Srinivasan			
	AM	5,721,340	02/1998	Halazonetics			
	AN	5,723,286	03/1998	Dower			
	AO	5,763,733	06/1998	Whitlow			
	AP	5,807,706	09/1998	Carter			
	AQ	5,821,333	10/1998	Carter			
	AR	5,837,242	11/1998	Holliger			
	AS	5,856,456	01/1999	Whitlow			
	AT	5,869,620	02/1999	Whitlow			
	AU	5,932,448	08/1999	Tso			
	AV	5,965,712	10/1999	Conrad			
	AW	6,025,165	02/2000	Whitlow			
	AX	6,027,725	02/2000	Whitlow			
	AY	6,071,515	06/2000	Mezes			
	AZ	6,121,424	09/2000	Whitlow			
	AAA	6,190,886	02/2001	Hoppe			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

In addition, Applicant would like to cross-reference the following U.S. applications:


<u>U.S. App. Serial. No.</u>	<u>Filing Date</u>
09/674,014	02/08/2001
09/555,446	08/16/2000
10/199,957	07/19/2002

<u>PCT App. Serial No.</u>	<u>Filing Date</u>
PCT/US02/23303	07/19/2002
PCT/US02/23002	07/19/2002
PCT/US98/25422	11/30/1998
PCT/UIS99/06537	04/19/1999

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 C.F.R. §1.56. The filing of this Information Disclosure Statement is not an admission by Applicants or Applicants' representatives that any of the documents, singly or in any combination, is effective as prior art against the subject application. Additionally, in accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists in addition to those submitted herewith.

Applicants respectfully request that the Examiner review the foregoing documents and information and that they be made of record in the file history of the subject application.

Respectfully submitted,

By: 
 James W. Collett, Ph.D.
 Reg. No. 46,636

DUANE MORRIS LLP
 101 West Broadway, Suite 900
 San Diego, CA 92101-8285
 (O) (619) 744-2200
 (F) (619) 744-2201

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3799-00010	Application No. 09/910,483
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Fang Fang et al.	
		Filing Date July 19, 2001	Group Art Unit 1648

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	ABB	6,307,026	10/2001	King			
	ACC	6,329,507	12/2001	Mezes			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	ADD	93/11161	06/1993	WIPO				
	AEE	93/11162	06/1993	WIPO				
	AFF	93/15210	09/1993	WIPO				
	AGG	94/13804	06/1994	WIPO				
	AHH	95/08577	03/1995	WIPO				
	AII	96/13583	05/1996	WIPO				
	AJJ	96/37621	11/1996	WIPO				
	AKK	98/50431	11/1998	WIPO				
	ALL	99/10510	03/1999	WIPO				
	AMM	00/09073	02/2000	WIPO				
	ANN	01/00814 A3	01/2001	WIPO				
	AOO	01/19842 A1	03/2001	WIPO				
	APP	0654085B1	05/1995	Europe				
	AQQ	365837 B1	08/1995	Europe				
	ARR	0672142 B1	09/1995	Europe				
	ASS							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ATT	Fang et al. "Antiviral Research", 53(3);pA65 march 2002, Conference/Meeting: Fifteenth International Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002
	AUU	Harbury et al., Science, 262: 1401-1407, 1993
	AVV	Pescini et al., Journal of Biological Chemistry, 269(2):1159-1165, 1994

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. E3799-00010	Application No. 09/910,483
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Fang Fang et al.	
		Filing Date July 19, 2001	Group Art Unit 1648

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AWW	Hodits et al., (1995) "An antibody Fragment from a Phage Display Library Competes for Ligand Binding to the Low Density Lipoprotein Receptor Family and Inhibits Rhinovirus Infection", J. Biol. Chem. 270(41): 24078-24085
	AXX	Hofer et al. (1994) "Members of the low density lipoprotein receptor family mediate cell entry of a minor group common cold virus", Proc. Natl. Acad. Sci. USA 91:1839-1842
	AYY	Welply et al. (1996) "A Peptide Isolated by Phage Display Binds to ICAM-1 and Inhibits Binding to LFA-1 PROTEINS: Structure, Function, and Genetics 26:262-270
	AZZ	Karush, F. et al., "Multivalence and affinity of antibody", Int. Arch. Allergy Appl. Immunol. 45(1-2):130-132 (1973)
	AAAA	Pack, Peter et al., "Tetravalent miniantibodies with high avidity assembling in Escherichia coli", J. Mol. Biol. 246(1):28-34 (1995)
	ABBB	Kipriyanov et al., "Affinity enhancement of recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Engineering (1996) Vol. 9, No. 2, pp. 203-211
	ACCC	Lou, Guang X. et al., "Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement", Journal of Immunological Methods, 275 (2003) 31-40
	ADDD	Pestov D. G. et al., "Genetic selection of growth-inhibitory sequences in mammalian cells", Proceedings of the National Academy of Science, Vol. 91, No. 26, December 20, 1994
	AEEE	Kamtekar S. et al., "Protein design by binary patterning of polar and nonpolar amino acids", Science, December 10, 1993, Vol. 262, no. 5140. pp. 1680-1685
	AFFF	Holsworth Daniel D. et al., "Antisense-designed peptides: A comparative study focusing on possible complements to angiotensin II", Peptide Research, Vol. 7, No. 4, 1994, pp. 185-193

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	